비교리스트

 카트 문의
시장보고서
상품코드
1563980

세계의 유방암 스크리닝 시장

Breast Cancer Screening
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 194 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

유방암 스크리닝 시장은 2030년까지 83억 달러에 달할 전망입니다.

2023년에 59억 달러로 추정된 유방암 스크리닝 시장은 예측 기간 동안 복합 연간 성장률(CAGR) 5.1%로 성장해 2030년에는 83억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 이미징 검사는 복합 연간 성장률(CAGR) 5.8%로 성장을 지속하고, 분석 기간이 끝날 때 48억 달러에 달할 것으로 예측됩니다. 면역조직화학 검사 분야의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 4.6%로 추정됩니다.

미국 시장은 15억 달러로 추정, 중국은 복합 연간 성장률(CAGR) 8.0%로 성장할 것으로 예측됩니다.

미국 유방암 스크리닝 시장은 2023년 15억 달러로 추정됐습니다. 세계의 2위 경제대국인 중국은 2030년까지 19억 달러 규모에 이를 것으로 예측되며, 예측 기간 동안 복합 연간 성장률(CAGR)은 8.0%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR)은 각각 3.0%와 4.1%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 3.8%로 성장할 것으로 예측됩니다.

세계의 유방암 스크리닝 시장 - 주요 동향과 촉진요인 요약

유방암 스크리닝이 조기 발견에 필수적인 이유란?

유방암 스크리닝은 세계의 수백만 명의 여성이 앓고 있는 유방암의 조기 발견에 있어 매우 중요한 역할을 하고 있습니다. 검진의 첫 번째 목적은 증상이 밝혀지기 전에도 초기 단계에서 암을 발견하는 것입니다. 유방 조직의 이상을 검출하기 위해 유방 조영술, 초음파, MRI, 유전자 검사 등의 기술이 이용됩니다. 그 중에서도 유방 조영술은 건강 진단에서 느껴지지 않는 작은 종양을 발견 할 수 있기 때문에 현재에도 가장 널리 권장되고 사용되는 방법입니다. 정기 검진은 40세 이상의 여성과 유방암 가족력이 있는 여성에게 특히 중요합니다. 조기 그리고 효과적인 치료가 가능해지면 유방암에 의한 사망 위험을 대폭 줄일 수 있기 때문입니다.

기술은 유방암 스크리닝에 어떤 혁명을 가져왔는가?

유방암 스크리닝의 분야는 기술 혁신에 의해 크게 진보해 이전보다 정밀하고 침습성이 낮고 보다 친밀한 것이 되었습니다. 주요 발전 인 디지털 유방 조영술은 이미지의 선명도를 향상시키고 미세한 이상을 발견 할 수있게했습니다. 이 기술은 또한 이미지의 저장과 공유를 용이하게 하고 환자 관리에서 보다 협력적이고 정보 기반의 의사 결정을 가능하게 합니다. 게다가 3D 유방 조영술(Tomosynthesis)은 유방 조직의 다차원적인 뷰를 제공함으로써 위양성을 줄이고 진단의 정확성을 향상시키는 획기적인 기술로 등장했습니다. 인공지능(AI)을 검진 과정에 도입하는 것도 변혁적인 도약이며, AI 도구는 현재 방사선과 의사를 지원하고 다른 방법으로는 간과될 수 있는 암의 미묘한 징후를 특정하는 것 수 있습니다. 이러한 기술적 진보는 유방암 스크리닝의 정확성을 높일 뿐만 아니라 프로세스를 보다 효율적으로 만들어 환자의 결과를 개선하고 있습니다.

유방암 스크리닝의 장래를 형성하는 새로운 동향이란?

유방암 스크리닝을 둘러싼 환경은 급속히 진화하고 있으며, 몇 가지 새로운 동향이 이 중요한 헬스케어 서비스의 장래의 무대가 되고 있습니다. 현저한 동향은 유전, 연령, 유방 밀도와 같은 개별 위험 요인을 고려하여 검진 프로토콜을 조정하는 개별화 검진 접근법으로의 전환입니다. 이 개별화된 접근법은 과다 진단 및 불필요한 치료와 관련된 위험을 줄이면서 검진의 효과를 극대화하려고 합니다. 또 다른 새로운 동향은 조영 유방 조영술과 유방 MRI와 같은 고급 이미지 기술의 사용이 증가하고 있다는 것입니다. 또한 AI를 스크리닝 검사에 통합하는 움직임도 활발해지고 있으며, 방사선과 의사에게 진단 정밀도와 효율을 향상시키는 고급 도구를 제공합니다. 또한, 충분한 서비스를 받지 못한 지역에서 검진 서비스에 대한 접근을 확대하고, 지리적,경제적 환경에 관계없이 모든 여성들이 조기 발견의 혜택을 누릴 수 있는 기회를 얻을 수 있도록 주목을 받고 있습니다. 이러한 동향은 이 분야에서 큰 기술 혁신을 촉진하고 유방암 스크리닝이 다양한 사람들의 요구에 적응하고 계속 진보하는 것을 확실히 하고 있습니다.

유방암 스크리닝 시장의 성장을 가속하고 있는 요인은?

유방암 스크리닝시장의 성장은 기술적 진보, 진화하는 헬스케어 프랙티스, 의식의 고조의 조합에 의해 촉진되고 있습니다. 주요 촉진요인 중 하나는 3D 유방 조영술의 보급과 이미지 처리에서 AI의 통합 등 검진 기술의 지속적인 기술 혁신으로 암 검출의 정확성과 신뢰성이 향상되고 있습니다. 또한 조기 발견이 생존율 향상에 필수적이기 때문에 특히 고령화 사회에서 유방암 이환율 상승도 검진 서비스 수요 증가에 기여하고 있습니다. 게다가, 개인화된 의료 동향은 유전자 검사 및 기타 위험 평가 도구 시장을 확대하고 있습니다. 공중 보건에 대한 노력과 의식 향상 캠페인은 특히 확립된 건강 관리 시스템이 이러한 서비스에 쉽게 접근할 수 있는 지역에서 정기적인 스크리닝 참가율을 크게 높였습니다. 이러한 요인이 종합적으로 유방암 스크리닝 시장의 견조한 확대를 지원하고 있으며, 기술의 진보와 세계의 인구의 요구의 변화에 따라 계속 진화하고 있습니다.

조사 대상 기업 예(전 42건)

  • A&G Pharmaceutical, Inc.
  • Agendia NV
  • Biocrates Life Sciences AG
  • Hologic, Inc.
  • Metabolomic Technologies Inc.
  • Myriad Genetics, Inc.
  • Quest Diagnostics, Inc.
  • Roche Diagnostics

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

BJH 24.10.08

Global Breast Cancer Screening Market to Reach US$8.3 Billion by 2030

The global market for Breast Cancer Screening estimated at US$5.9 Billion in the year 2023, is expected to reach US$8.3 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2023-2030. Imaging Test, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Immunohistochemistry Test segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 8.0% CAGR

The Breast Cancer Screening market in the U.S. is estimated at US$1.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Breast Cancer Screening Market - Key Trends and Drivers Summarized

Why Is Breast Cancer Screening Crucial for Early Detection?

Breast cancer screening plays a pivotal role in the early detection of breast cancer, a prevalent disease that affects millions of women worldwide. The primary goal of screening is to identify cancer in its earliest stages, even before symptoms become apparent, thus allowing for timely and potentially life-saving treatments. Techniques such as mammography, ultrasound, MRI, and genetic testing are utilized to detect abnormalities in breast tissue. Among these, mammography remains the most widely recommended and utilized method due to its ability to detect small tumors that might not be felt during a physical examination. Regular screening is especially important for women over 40 or those with a family history of breast cancer, as it can significantly reduce the risk of death from the disease by enabling earlier and more effective treatment.

How Has Technology Revolutionized Breast Cancer Screening?

The field of breast cancer screening has been significantly advanced by technological innovations, making the process more precise, less invasive, and more accessible than ever before. Digital mammography, a key development, has improved the clarity of images and allowed for better detection of minute abnormalities. This technology also facilitates easier storage and sharing of images, enabling more collaborative and informed decision-making in patient care. Furthermore, 3D mammography, or tomosynthesis, has emerged as a game-changer by providing a multi-dimensional view of breast tissue, which reduces false positives and improves the accuracy of diagnoses. The incorporation of artificial intelligence (AI) into the screening process is another transformative leap, with AI tools now capable of assisting radiologists in identifying subtle signs of cancer that might otherwise be overlooked. These technological advancements are not only enhancing the accuracy of breast cancer screening but are also making the process more efficient, thereby improving outcomes for patients.

What New Trends Are Shaping the Future of Breast Cancer Screening?

The landscape of breast cancer screening is rapidly evolving, with several new trends setting the stage for the future of this critical healthcare service. A prominent trend is the move towards personalized screening approaches, where individual risk factors such as genetics, age, and breast density are taken into account to tailor screening protocols. This personalized approach seeks to maximize the effectiveness of screening while reducing the risks associated with overdiagnosis and unnecessary treatments. Another emerging trend is the increasing use of advanced imaging technologies like contrast-enhanced mammography and breast MRI, which offer more detailed visualization and are particularly beneficial for individuals at higher risk. The integration of AI into screening procedures is also gaining traction, providing radiologists with advanced tools to improve diagnostic accuracy and efficiency. Additionally, there is a growing focus on expanding access to screening services in underserved communities, ensuring that all women have the opportunity to benefit from early detection, regardless of their geographic or economic circumstances. These trends are driving significant innovation in the field, ensuring that breast cancer screening continues to advance and adapt to the needs of diverse populations.

What Factors Are Fueling Growth in the Breast Cancer Screening Market?

The growth in the breast cancer screening market is fueled by a combination of technological advancements, evolving healthcare practices, and increasing awareness. One of the key drivers is the ongoing innovation in screening technologies, such as the widespread adoption of 3D mammography and the integration of AI in imaging, which are improving the accuracy and reliability of cancer detection. The rising incidence of breast cancer, especially among aging populations, is also contributing to the increased demand for screening services, as early detection is critical for improving survival rates. Furthermore, the trend towards personalized medicine is expanding the market for genetic testing and other risk assessment tools, as more screening programs are tailored to individual risk profiles. Public health initiatives and awareness campaigns have significantly boosted participation rates in regular screening, particularly in regions where established healthcare systems provide easy access to these services. These factors are collectively supporting the robust expansion of the breast cancer screening market, as it continues to evolve in response to technological advancements and the changing needs of the global population.

Select Competitors (Total 42 Featured) -

  • A&G Pharmaceutical, Inc.
  • Agendia NV
  • Biocrates Life Sciences AG
  • Hologic, Inc.
  • Metabolomic Technologies Inc.
  • Myriad Genetics, Inc.
  • Quest Diagnostics, Inc.
  • Roche Diagnostics

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Breast Cancer Screening - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Breast Cancer Propels Demand for Advanced Screening Methods
    • Increased Awareness and Early Detection Efforts Expand Addressable Market Opportunity
    • Advancements in Imaging Techniques Strengthen the Business Case for Enhanced Screening Tools
    • Growing Adoption of 3D Mammography Spurs Growth in Breast Cancer Screening
    • Rising Demand for Non-Invasive Screening Options Generates Need for Advanced Diagnostic Methods
    • Expansion of National Screening Programs Sustains Growth in the Breast Cancer Screening Market
    • Advances in Genetic Testing Propel Innovation in Risk-Based Screening Strategies
    • Rising Demand for Portable and Accessible Screening Devices Expands Market for Mobile Screening Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Breast Cancer Screening Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Breast Cancer Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Breast Cancer Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Breast Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Imaging Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Imaging Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Imaging Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunohistochemistry Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immunohistochemistry Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Immunohistochemistry Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Genetic Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Genetic Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Genetic Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Blood Marker Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Blood Marker Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Blood Marker Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • JAPAN
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • CHINA
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: China 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • EUROPE
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Breast Cancer Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Breast Cancer Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Breast Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • FRANCE
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: France 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • GERMANY
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 47: Spain Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Spain Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Spain 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 50: Russia Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Russia Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Russia 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Breast Cancer Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Breast Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 62: Australia Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Australia Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Australia 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • INDIA
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 65: India Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: India Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: India 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 68: South Korea Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: South Korea Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: South Korea 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Rest of Asia-Pacific Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Rest of Asia-Pacific 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Breast Cancer Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Breast Cancer Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Breast Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 80: Argentina Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Argentina Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Argentina 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 83: Brazil Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Brazil Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Brazil 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 86: Mexico Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Mexico Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Mexico 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Latin America Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Latin America 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Breast Cancer Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Breast Cancer Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Breast Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 98: Iran Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Iran Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Iran 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 101: Israel Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Israel Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Israel 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Saudi Arabia Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Saudi Arabia 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 107: UAE Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UAE Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: UAE 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Middle East Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Middle East 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • AFRICA
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 113: Africa Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Africa Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Africa 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제